4th Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$560,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Pharmacy issues, prescription drug supply chain issues, including security of the supply chain, drug shortages, prescription drug abuse and diversion. H.R. 1919 "Safeguarding America's Pharmaceuticals Act of 2013". S. 957 "Drug Supply Chain Security Act". S. 959 "Pharmaceutical Quality, Security and Accountability Act"

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1919 (113th), S. 957 (113th), S. 959 (113th)

Taxation/Internal Revenue Code TAX

Proposals to repeal LIFO

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Veterans VET

Existing Department of Veterans' Affairs Pharmaceutical Prime Vendor contract.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Incentives for health information technology, Affordable Care Act implementation, and other healthcare policy issues. Proposed regulation of medical software.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H.R. 1416 "Cancer Patient Protection Act of 2013"S.806/H.R. 800 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —
MATT BROW —
KEAGAN R LENIHAN —
GEOFF WERTH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 800 (113th), S. 806 (113th), H.R. 1416 (113th), H.R. 2869 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.